Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Moore

Showing results (611-620 of 613) with videos related to

Pageof 62
Sort By:
You have reached the last page of results.This site can display upto 613 results.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2020
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew D J Pearson, C Michel Zwaan, E Anders Kolb, et al.
Cancer Research|September 24, 2025
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated CancersMichael Hulse, Min Wang, Chaoyi Xu, et al.
Nature Communications|December 3, 2024
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 yearsMichelle A Neller, George R Ambalathingal, Nada Hamad, et al.
Pageof 62

Showing results (611-620 of 613) with videos related to

Sort By:
Pageof 62
You have reached the last page of results.This site can display upto 613 results.
European Journal of Cancer (Oxford, England : 1990)|July 21, 2020
Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug AdministrationAndrew D J Pearson, C Michel Zwaan, E Anders Kolb, et al.
Cancer Research|September 24, 2025
PRT3789 Is a First-in-Human SMARCA2-Selective Degrader That Induces Synthetic Lethality in SMARCA4-Mutated CancersMichael Hulse, Min Wang, Chaoyi Xu, et al.
Nature Communications|December 3, 2024
Compassionate access to virus-specific T cells for adoptive immunotherapy over 15 yearsMichelle A Neller, George R Ambalathingal, Nada Hamad, et al.
Pageof 62